Gainers & Losers

Registered Office: #DPT-033 Gr Flr Plt #79-80 DLF,Prime Tower F Blo.Okhla Phase1, New Delhi - 110020, New Delhi, India.
Phone : +91-11 4656 1474   Fax:
Email :  cs@mahamayalifesciences.com  
Website :  https://www.mahamayalifesciences.com/

Initial public offer of up to 61,78,800* equity shares of face value of Rs. 10/- each ("Equity shares") of Mahamaya Lifesciences Limited ("MLL" or the "Company") for cash at price of Rs. [*] per equity share (including a share premium of [*] per equity share) (the "Offer Price"), aggregating up to Rs. [*] Crore ("the Offer"), comprising a fresh offer of upto 56,38,8008* equity shares aggregating to Rs. [*] Crore (the "Fresh Offer") and an offer for sale of upto 540,000* equity shares (the "Offered Shares") of face value of Rs. 10/- each aggregating up to Rs. [*] Crore ("offer for sale") comprising of 3,70,000* equity shares aggregating up to Rs. [*] Crore by Krishnamurthy Ganesan and 1,70,000* equity shares aggregating up to Rs. [*] Crore by Lalitha Krishnamurthy (collectively reffered to as the "Selling Shareholders") out of which 3,09,600 equity shares of face value Rs. 10/- each, at an offer price of Rs. [*] per equity share for cash, aggregating Rs. [*] crores will be reserved for subscription by the market maker to the offer (the "Market Maker Reservation Portion"). The offer less market maker reservation portion i.e. net offer of 58,69,200* equity shares of face value of Rs. 10/- each, at an offer price of Rs. [*] per equity share for cash, aggregating up to Rs. [*] crores is hereinafter referred to as the "Net Offer". The offer and net offer will constitute 26.40% and 25.08% respectively of the post-offer paid-up equity share capital of the company. Price Band: Rs. 108 to Rs. 114 per equity share of face value Rs. 10 each. The floor price is 10.8 times of the face value of the equity shares and the cap price is 11.4 times of the face value of the equity shares. Bids can be made for minimum of 2,400 equity shares and in multiples of 1,200 equity shares thereafter.